Streetbeat News

EOLS

Evolus, Inc.

https://www.evolus.com

Industry

Drug Manufacturers - Specialty & Generic

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Open

13.24

Mkt cap

837M

Volume

46K

High

13.49

P/E Ratio

-16.26

52-wk high

17.82

Low

13.13

Div yield

N/A

52-wk low

9.25

Evolus, Inc. held its Q4 2024 earnings call, discussing financial results and company updates. Key participants included executives and analysts from various firms.

Portfolio Pulse from

March 05, 2025 | 4:30 am

Evolus, Inc. (EOLS) reported Q4 earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06. This is an improvement from a loss of $0.14 per share a year ago.

Portfolio Pulse from

March 04, 2025 | 11:45 pm

Evolus, Inc. (NASDAQ: EOLS) reported record financial results for Q4 and full-year 2024, achieving profitability ahead of expectations and marking its fifth consecutive year of over 30% revenue growth. The company also reaffirmed its 2025 guidance.

Portfolio Pulse from

March 04, 2025 | 9:30 pm

Evolus (EOLS) saw a 5.5% increase in its stock price during the last trading session, driven by higher-than-average trading volume. However, the current trend in earnings estimate revisions may not support continued upward movement in the near term.

Portfolio Pulse from

February 14, 2025 | 3:15 pm

The U.S. FDA has approved Evolus' two new anti-wrinkle injectable gels, expanding its product portfolio beyond Jeuveau.

Portfolio Pulse from

February 13, 2025 | 7:00 pm

Evolus, Inc. has granted stock options and restricted stock units to new non-executive employees as part of its inducement grants under Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

February 08, 2025 | 12:30 am

Evolus, Inc. faces challenges despite previous positive outlook due to litigation settlement with AbbVie and strong revenue targets. The stock has fallen sharply, possibly due to market unpredictability and sector instability. Skepticism surrounds its ambitious revenue targets, but strong product performance and brand loyalty provide optimism.

Portfolio Pulse from

January 14, 2025 | 7:15 pm

Evolus, Inc. announced the grant of stock options and restricted stock units to new non-executive employees under Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

December 13, 2024 | 9:30 pm

Evolus (EOLS) is showing signs of a potential turnaround with a hammer chart pattern indicating support and Wall Street analysts revising earnings estimates higher.

Portfolio Pulse from

November 18, 2024 | 4:00 pm

Evolus (EOLS) has experienced a significant decline of 29.8% over the past four weeks, placing it in oversold territory. The selling pressure may have subsided, and with Wall Street analysts raising earnings estimates, a trend reversal could be on the horizon.

Portfolio Pulse from

November 14, 2024 | 3:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.